The Novo, St. Jude and Kaiser Permanente-backed cardiac diagnostics technology developer floated above its range and closed its first day of trading 53% up on its IPO price.

Bayer invested $35m in the Switzerland-based gene editing company but it floated below its range and lowered the number of shares in the offering.

Pain assessment technology developer ePat is set to list on the Australian Stock Exchange today, providing an exit to Curtin University.

The pharmaceutical developer, which has raised more than $85m from investors including Novo, Novartis and Amgen, has set the range for its initial public offering.

The advanced electrocardiogram developer, spun out of Stanford University, has set the range for an initial public offering sized at up to $91m.

Shareholders in the semiconductor memory technology provider include Western Digital and GlobalFoundries, while GigaDevice Semiconductor is investing $5m.

Crispr Therapeutics, a gene editing drug developer backed by Bayer, Vertex, Celgene and GlaxoSmithKline, has set the terms for an offering on Nasdaq.

E.ON-backed fuel cell system producer Bloom Energy has reportedly filed for an initial public offering, one likely to value it at less than its previous $2.9bn valuation.

The gastric balloon developer has gone public, after raising more than $70m in debt and equity from investors including Bader Sultan & Bros and AmorePacific.